Skip to main content

A Review of the Pharmacokinetics of Cefpodoxime Proxetil

Summary

Cefpodoxime proxetil is an orally absorbed broad spectrum third generation cephalosporin antibacterial. It is a prodrug that is de-esterified in vivo to its active metabolite, cefpodoxime. After single- and multiple-dose (12-hourly) administration of cefpodoxime proxetil in the therapeutic dose range of 100 to 400mg of cefpodoxime equivalents, average peak plasma concentrations of cefpodoxime range from 1.0 to 4.5 mg/L and occur between 1.9 and 3.1 hours after administration. The half-life of cefpodoxime ranges from 1.9 to 2.8 hours. The absolute bioavailability of cefpodoxime proxetil tablets is 50%, and absorption is enhanced by concomitant administration of food. Raising gastric pH by pretreatment with antacids or H2-receptor antagonists results in reduced absorption. Binding of cefpodoxime to human plasma or serum protein is low ( 18 to 23%), suggesting that cefpodoxime should readily transfer across the capillary lining into tissues. Cefpodoxime undergoes minimal metabolism in humans. Drug not absorbed is degraded in the gastrointestinal tract and excreted in the faeces. As expected for a drug eliminated primarily by renal excretion, the disposition of cefpodoxime is altered in patients with impaired renal function; the half-life increases, while apparent plasma clearance and renal clearance decrease. The pharmacokinetics of cefpodoxime after oral administration of cefpodoxime proxetil are not affected by age.

This is a preview of subscription content, access via your institution.

References

  • Backhouse C, Wade A, Williamson P, Tremblay D, Lenfant B. Multiple-dose pharmacokinetics of cefpodoxime in young adult and elderly patients. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 29–34, 1990

    PubMed  Article  Google Scholar 

  • Bombardt PA, Cathcart KS, Bothwell BE, Closson SK. Determination of cefpodoxime levels and cefpodoxime stability in human urine by direct injection HPLC with column-switching. Journal of Liquid Chromatography 14: 1729–1746, 1991

    Article  CAS  Google Scholar 

  • Borin MT, Hughes GS, Patel RK, Royer ME. Pharmacokinetic and tolerance studies of cefpodoxime after single and multiple dose oral administration of cefpodoxime proxetil. Journal of Clinical Pharmacology, in press, 1991

  • Borin MT, Hughes GS, Spillers CR, Patel RK. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrobial Agents and Chemotherapy 34: 1094–1099, 1990

    PubMed  Article  CAS  Google Scholar 

  • Cho N, Fukunaga K, Kunii K, Kimura T, Suzuki A. Basic and clinical studies on CS-807 in the obstetric and gynecological field. Chemotherapy (Tokyo) 36 (Suppl. 1): 923–940, 1988

    Google Scholar 

  • Couraud L, Andrews JM, Lecoeur H, Sultan E, Lenfant B. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 35–40, 1990

    PubMed  Google Scholar 

  • Dumont R, Guetat F, Andrews JM, Sultan E, Lenfant B. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 41–46, 1990

    PubMed  Google Scholar 

  • Fass RJ, Helsel VL. In vitro activity of U-76,252 (CS-807), a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 32: 1082–1085, 1988

    PubMed  Article  CAS  Google Scholar 

  • Fujii A, Maeda H, Yamazaki H, Arakawa S, Kamidono S. Clinical studies on CS-807 in the urological field. Chemotherapy (Tokyo) 36 (Suppl. 1): 788–801, 1988

    Google Scholar 

  • Fujii R, Meguro H, Arimasu O, Shiraishi H, Abe T, et al. Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields. Japanese Journal of Antibiotics 42: 1439–1455, 1989

    PubMed  CAS  Google Scholar 

  • Fukami K, Furuta S, Fukuda K, Kiyota R, Imakiire T, et al. Basic and clinical studies on CS-807 in infections in the otorhinolaryngological field. Chemotherapy (Tokyo) 36 (Suppl. 1): 1067–1073, 1988

    Google Scholar 

  • Gehanno P, Andrews JM, Ichou F, Sultan E, Lenfant B. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 47–51, 1990

    PubMed  Google Scholar 

  • Hayashi I, Ohnuma K. Clinical results of CS-807 on acute exacerbation of chronic bronchitis. Chemotherapy (Tokyo) 36 (Suppl. 1): 386–390, 1988

    Google Scholar 

  • Hisaoka M, Ichikawa M, Kojima T. Microbiological assay for determining the CS-807 concentration in body fluids. Chemotherapy (Tokyo) 36 (Suppl. 1): 185–193, 1988

    CAS  Google Scholar 

  • Hoffler D, Koeppe P, Corcilius M, Przyklink A. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection 18: 157–162, 1990

    PubMed  Article  CAS  Google Scholar 

  • Hoshino M, Mogi S, Takahashi H. Clinical evaluation of CS-807 against skin and soft tissue infections. Chemotherapy (Tokyo) 36 (Suppl. 1): 1074–1078, 1988

    Google Scholar 

  • Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clinical Pharmacology and Therapeutics 46: 674–685, 1989

    PubMed  Article  CAS  Google Scholar 

  • Hughes GS, Heald DL, Patel R, Spillers CR, Batts DH, et al. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil. Methods and Findings in Experimental and Clinical Pharmacology 12: 197–204, 1990

    PubMed  CAS  Google Scholar 

  • Ishibashi H, Ohta K, Kudo K, Kabe J. CS-807 in respiratory tract infections. Chemotherapy (Tokyo) 36 (Suppl. 1): 419–423, 1988

    Google Scholar 

  • Iwai N, Taneda Y, Nakamura H, Miyazu M, Kasai K. Pharmacokinetic bacteriological and clinical evaluation of cefpodoxime proxetil in pediatrics. Japanese Journal of Antibiotics 42: 1571–1592, 1989

    PubMed  CAS  Google Scholar 

  • Jones RN, Barry AL. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrobial Agents and Chemotherapy 32: 443–449, 1988

    PubMed  Article  CAS  Google Scholar 

  • Jones RN, Barry AL, Pfaller M, Allen SD, Iyers LW, et al. Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control. Diagnostic Microbiology and Infectious Diseases 9: 59–63, 1988

    Article  CAS  Google Scholar 

  • Kobayashi K, Shimizu Y, Shiota K. CS-807 in respiratory tract infection. Chemotherapy (Tokyo) 36 (Suppl. 1): 515–521, 1988

    Google Scholar 

  • Komai T, Kawai K, Tsubaki H, Tokui T, Kinoshita T, et al. Absorption, distribution, metabolism and excretion of CS-807, a new oral cephem antibiotic, in experimental animals. Chemotherapy (Tokyo) 36 (Suppl. 1): 229–240, 1988

    CAS  Google Scholar 

  • Matsumoto T, Matsuda T, Urabe H. CS-807 in bacterial infections of the skin. Chemotherapy (Tokyo) 36 (Suppl. 1): 1106–1110, 1988

    Google Scholar 

  • Molina F, Jehl F, Gallion C, Penner F, Monteil H. Determination of the third generation oral cephalosporin cefpodoxime in biological fluids by high-speed high-performance liquid chromatography. Journal of Chromatography and Biomedical Applications 563: 205–210, 1991

    Article  CAS  Google Scholar 

  • Naber KG, Kinzig M, Adam D, Sorgel F, Bajorski AH, et al. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection 19: 30–35, 1991

    PubMed  Article  CAS  Google Scholar 

  • Nakayama I, Yamaji E, Kawamura H, Kawaguchi H, Akieda Y, et al. Clinical application of CS-807, an oral cephalosporin antibiotic, to skin and soft tissue infections. Chemotherapy (Tokyo) 36 (Suppl. 1): 620–647, 1988

    Google Scholar 

  • Niino K, Sato H, Narita A, Nakazawa S, Suzuki H, et al. Evaluation of cefpodoxime proxetil in the pediatric field. Japanese Journal of Antibiotics 42: 1505–1518, 1989

    PubMed  CAS  Google Scholar 

  • O’Neill P, Nye K, Llouce G, Andrews J, Wise R. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrobial Agents and Chemotherapy 34: 232–234, 1990

    PubMed  Article  Google Scholar 

  • Patel RK. Development and validation of microbioassay for cefpodoxime. 90th Meeting of the American Society for Microbiology, Anaheim, California, May 13–17, 1990. Abstract no. A142, 1990

  • Safran C. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 93–101, 1990

    PubMed  Google Scholar 

  • Sekine M, Sasahara K, Ichikawa M. High-performance liquid Chromatographic method for determing the CS-807 concentration in body fluids. Chemotherapy (Tokyo) 36 (Suppl. 1): 194–199, 1988

    CAS  Google Scholar 

  • Shinkawa A, Tamura Y, Shimizu K, Miyake H. CS-807 in otorhinolaryngological infections. Chemotherapy (Tokyo) 36 (Suppl. 1): 1046–1055, 1988

    Google Scholar 

  • Steenwyk RC, Brewer JE, Royer ME, Cathcart KS. Reversed-phase liquid Chromatographie determination of cefpodoxime in human plasma. Journal of Liquid Chromatography Clinical Analysis, in press, 1991

  • St Peter JV, Borin MT, Kelloway JS, Shapiro BE, Halstenson CE. Cefpodoxime proxetil disposition in patients with various degrees of renal function. Journal of Clinical Pharmacology 30: 838, 1990

    Google Scholar 

  • Takizawa K, Ino Y, Iguchi T, Takeda Y. Antibacterial and clinical effects of a newly synthesized antibiotic, CS-807, in gynecological infections. Chemotherapy (Tokyo) 36 (Suppl. 1): 903–906, 1988

    Google Scholar 

  • Tremblay D, Dupront A, Ho C, Coussediere D, Lenfant B. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 21–28, 1990

    PubMed  Article  CAS  Google Scholar 

  • Uchida E, Oguchi K, Hisaoka M, Kobyashi S, Kai K, et al. Effects of ranitidine, metoclopramide, and anisotropine methylbromide on the availability of cefpodoxime proxetil (CS-807) in Japanese healthy subjects. Japanese Journal of Clinical Pharmacology and Therapeutics 19: 573–579, 1988

    Article  CAS  Google Scholar 

  • Ueda S, Hayashi K, Okabe T, Yoshizumi O, Yamashita T, et al. Fundamental and clinical studies on CS-807. Chemotherapy (Tokyo) 36 (Suppl. 1): 859–867, 1988

    Google Scholar 

  • Utsui Y, Inoue M, Mitsuhashi S. In vitro and in vivo antibacterial properties of CS-807, a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 31: 1085–1092, 1987

    PubMed  Article  CAS  Google Scholar 

  • Wise R. The pharmacokinetics of the oral cephalosporins — a review. Journal of Antimicrobial Chemotherapy 26 (Suppl. E): 13–20, 1990

    PubMed  CAS  Google Scholar 

  • Yamamoto T, Yasuda SJ, Kanao M, Okada H. CS-807 in the field of obstetics and gynecology. Chemotherapy (Tokyo) 36 (Suppl. 1): 967–978, 1988

    Google Scholar 

  • Yamasaki A, Seo K, Sanda N, Seko S, Nakano H, et al. CS-807 in urinary tract infections. Chemotherapy (Tokyo) 36 (Suppl. 1): 813–818, 1988

    Google Scholar 

  • Yokota T, Suzuki E, Arai K. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages. Drugs Under Experimental and Clinical Research 14: 495–500, 1988

    PubMed  CAS  Google Scholar 

  • Yura J, Shinagawa N, Mizuno A, Mashita K, Taniguchi M, et al. CS-807 in surgery. Chemotherapy (Tokyo) 36 (Suppl. 1): 664–676, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Borin, M.T. A Review of the Pharmacokinetics of Cefpodoxime Proxetil. Drugs 42 (Suppl 3), 13–21 (1991). https://doi.org/10.2165/00003495-199100423-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199100423-00005

Keywords

  • Pleural Fluid
  • Cefpodoxime
  • Urinary Recovery
  • Borin
  • Oral Cephalosporin